BiotechTube
Genprex

Genprex

GNPXPhase 2
11-50 employeesgenprex.com

Genprex is focused on developing life-changing gene therapies for cancer patients, leveraging its unique platform to deliver tumor suppressor genes directly to cancer cells. The company's core technology, the ONCOPREX® Nanoparticle Delivery System, is designed to overcome the limitations of viral vectors and enable systemic administration. Its lead program, Reqorsa®, which delivers the TUSC2 gene, is in multiple clinical trials for lung cancer, positioning the company at the forefront of non-viral gene therapy in oncology. Genprex's strategy involves advancing its pipeline through clinical development and seeking strategic partnerships to maximize the potential of its platform.

Market Cap
$3.1M
-90.3% period
Pipeline
4
drug candidates
Patents
—
Publications
—

GNPX · Stock Price

USD 1.8817.42 (-90.26%)

Historical price data

AI Company Overview

Genprex is focused on developing life-changing gene therapies for cancer patients, leveraging its unique platform to deliver tumor suppressor genes directly to cancer cells. The company's core technology, the ONCOPREX® Nanoparticle Delivery System, is designed to overcome the limitations of viral vectors and enable systemic administration. Its lead program, Reqorsa®, which delivers the TUSC2 gene, is in multiple clinical trials for lung cancer, positioning the company at the forefront of non-viral gene therapy in oncology. Genprex's strategy involves advancing its pipeline through clinical development and seeking strategic partnerships to maximize the potential of its platform.

OncologyLung Cancer

Technology Platform

The ONCOPREX® Nanoparticle Delivery System is a proprietary, non-viral platform that uses lipid nanoparticles to systemically deliver tumor suppressor gene therapies directly to cancer cells.

Pipeline

4
4 drugs in pipeline
DrugIndicationStageWatch
quaratusugene ozeplasmid + osimertinib + Platinum-Based Chem...Carcinoma, Non-Small Cell LungPhase 1/2
quaratusugene ozeplasmid + pembrolizumab + docetaxel + ramuc...Non Small Cell Lung CancerPhase 1/2
quaratusugene ozeplasmid + atezolizumabSmall Cell Lung Cancer Extensive StagePhase 1/2
DOTAP:Chol-TUSC2 + Erlotinib + Dexamethasone + Diphenhydrami...Lung CancerPhase 1/2

Funding History

2
Total raised:$22M
PIPE$10MFeb 15, 2021
IPO$12MJul 15, 2018

Opportunities

Genprex's primary growth opportunity lies in successfully demonstrating that Reqorsa® can overcome resistance to leading therapies like Tagrisso® and Tecentriq®, potentially capturing significant market share in later-line lung cancer treatment.
Further opportunities include expanding the ONCOPREX® platform to deliver other therapeutic genes and targeting additional cancer indications beyond lung cancer.

Risk Factors

Key risks include the high likelihood of clinical trial failure inherent to drug development, ongoing dependence on raising additional capital leading to shareholder dilution, intense competition in the oncology space, and the uncertainty of regulatory approval even with positive data.

Competitive Landscape

Genprex competes with large pharma oncology leaders and other gene therapy biotechs. Its main differentiation is its non-viral ONCOPREX® delivery platform and the unique multi-mechanistic action of its TUSC2 gene therapy, which is designed to restore tumor suppressor function and synergize with existing standards of care in combination regimens.